Cyril Quivoron

Dr. Cyril Quivoron

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Cancer Cell
Verified
Journal Article
Closed access
CQCyril Quivoron
Cyril Quivoron
LCLucile Couronné
Lucile Couronné
VVVéronique Della Valle
Véronique Della Valle
CLCécile K. Lopez
Cécile K. Lopez
IPIsabelle Plo
Isabelle Plo
OBOlivier A. Bernard
Olivier A. Bernard

3 May 2013 in Science
Verified
Journal Article
Closed access
PDF file
FWFang Wang
Fang Wang
JTJeremy Travins
Jeremy Travins
BDByron DeLaBarre
Byron DeLaBarre
VPVirginie Penard-Lacronique
Virginie Penard-Lacronique
SSStefanie Schalm
Stefanie Schalm
KYKatharine E. Yen
Katharine E. Yen
IDHology: Among the most exciting drug targets to emerge from cancer genome sequencing projects are two related metabolic enzymes, isocitrate dehydrogenases 1 and 2 (IDH1, IDH2). Mutations in the IDH1 and IDH2 genes are common in certain types of human cancer. Whether inhibition of mutant IDH activity might offer therapeutic benefits is unclear (see the Perspective by Kim and DeBerardinis ). F. Wang et al. (p. 622 , published online 4 April) isolated a small molecule that selectively inhibits mutant IDH2, describe the structural details of its binding to the mutant enzyme, and show that this compound suppresses the growth of patient-derived leukemia cells harboring the IDH2 mutation. Rohle et al. (p. 626 , published online 4 April) show that a small molecule inhibitor of IDH1 selectively slows the growth of patient-derived brain tumor cells with the IDH1 mutation.

30 April 2017 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KYKatharine Yen
Katharine Yen
JTJeremy Travins
Jeremy Travins
FWFang Wang
Fang Wang
MDMuriel D. David
Muriel D. David
EAErin Artin
Erin Artin
SSShin-San Michael Su
Shin-San Michael Su
Somatic gain-of-function mutations in isocitrate dehydrogenases (IDH) 1 and 2 are found in multiple hematologic and solid tumors, leading to accumulation of the oncometabolite (R)-2-hydroxyglutarate (2HG). 2HG competitively inhibits α-ketoglutarate–dependent dioxygenases, including histone demethylases and methylcytosine dioxygenases of the TET family, causing epigenetic dysregulation and a block in cellular differentiation. In vitro studies have provided proof of concept for mutant IDH inhibition as a therapeutic approach. We report the discovery and characterization of AG-221, an orally available, selective, potent inhibitor of the mutant IDH2 enzyme. AG-221 suppressed 2HG production and induced cellular differentiation in primary human IDH2 mutation–positive acute myeloid leukemia (AML) cells ex vivo and in xenograft mouse models. AG-221 also provided a statistically significant survival benefit in an aggressive IDH2R140Q-mutant AML xenograft mouse model. These findings supported initiation of the ongoing clinical trials of AG-221 in patients with IDH2 mutation–positive advanced hematologic malignancies. Significance: Mutations in IDH1/2 are identified in approximately 20% of patients with AML and contribute to leukemia via a block in hematopoietic cell differentiation. We have shown that the targeted inhibitor AG-221 suppresses the mutant IDH2 enzyme in multiple preclinical models and induces differentiation of malignant blasts, supporting its clinical development. Cancer Discov; 7(5); 478–93. ©2017 AACR. See related commentary by Thomas and Majeti, p. 459. See related article by Shih et al., p. 494. This article is highlighted in the In This Issue feature, p. 443

19 January 2018 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Open access
JPJaneta Popovici-Muller
Janeta Popovici-Muller
RLRené M. Lemieux
René M. Lemieux
EAErin Artin
Erin Artin
JSJeffrey O. Saunders
Jeffrey O. Saunders
FSFrancesco G. Salituro
Francesco G. Salituro
KYKatharine Yen
Katharine Yen
Somatic point mutations at a key arginine residue (R132) within the active site of the metabolic enzyme isocitrate dehydrogenase 1 (IDH1) confer a novel gain of function in cancer cells, resulting in the production of d-2-hydroxyglutarate (2-HG), an oncometabolite. Elevated 2-HG levels are implicated in epigenetic alterations and impaired cellular differentiation. IDH1 mutations have been described in an array of hematologic malignancies and solid tumors. Here, we report the discovery of AG-120 (ivosidenib), an inhibitor of the IDH1 mutant enzyme that exhibits profound 2-HG lowering in tumor models and the ability to effect differentiation of primary patient AML samples ex vivo. Preliminary data from phase 1 clinical trials enrolling patients with cancers harboring an IDH1 mutation indicate that AG-120 has an acceptable safety profile and clinical activity.

16 July 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
LQLynn Quek
Lynn Quek
MDMuriel D. David
Muriel D. David
AKAlison Kennedy
Alison Kennedy
MMMarlen Metzner
Marlen Metzner
MAMichael Amatangelo
Michael Amatangelo
PVParesh Vyas
Paresh Vyas

1 February 2014 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MJMaxime Janin
Maxime Janin
EMElena Mylonas
Elena Mylonas
VSVéronique Saada
Véronique Saada
JMJean-Baptiste Micol
Jean-Baptiste Micol
ARAline Renneville
Aline Renneville
SBStéphane de Botton
Stéphane de Botton
Purpose: Mutated isocitrate dehydrogenases (IDHs) 1 and 2 produce high levels of 2-hydroxyglutarate (2-HG). We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence of IDH1/2 mutations at diagnosis and provide a marker of minimal residual disease (MRD). Patients and Methods: Serum samples from 82 patients at diagnosis of de novo AML (IDH1/2 mutated, n = 53) and 68 patients without AML were analyzed for total 2-HG and its ratio of D to L stereoisomers by mass spectrometry. We measured 2-HG levels and molecular markers of MRD (WT1 and NPM1) in serial samples of 36 patients with IDH1/2 mutations after induction therapy. Results: In patients with AML with IDH1/2 mutations, 2-HG serum levels were significantly higher than in patients with IDH1/2 wild type (P < .001). Area under the receiver operating characteristic curve was 99%. The optimum diagnostic cutoff between IDH1/2 mutated and normal was 2 μmol/L (sensitivity, 100%; specificity, 79%). Quantification of the D/L stereoisomers increased specificity (100%; 95% CI, 83% to 100%) compared with total 2-HG (P = .031). In patients with IDH2 R172 mutations, 2-HG levels were higher relative to those with other IDH1/2 mutations (P < .05). During follow-up, serum 2-HG levels showed strong positive correlation with WT1 and NPM1 (P < .001). After induction therapy, total 2-HG serum levels < 2 μmol/L were associated with better overall (P = .008) and disease-free survival (P = .005). Conclusion: Serum 2-HG is a predictor of the presence of IDH1/2 mutations and outcome in these patients. Discrimination between D/L stereoisomers improved specificity.